Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

Dr. Goetz on the Use of ctDNA in the MONARCH-3 Trial in HR+/HER2- Breast Cancer

January 9th 2020

Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsies

January 9th 2020

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

Current Advancements in HER2+ Breast Cancer Management

December 24th 2019

HER2CLIMB-02 Trial Regimen Toxicities and Impact

December 24th 2019

The HER2CLIMB-02 Trial Design, Results and Implications

December 24th 2019

HER2+ Breast Cancer: Brain Metastasis Prevalence & Later-Line Therapy

December 24th 2019

Emerging Data for the Treatment of HER2+ mBC

December 24th 2019

HER2+ mBC: Systemic Therapies and HER2CLIMB-02 Trial

December 24th 2019

Management of CNS Metastases in R/R HER2+ mBC

December 24th 2019

HER2+ Metastatic Breast Cancer: Standard of Care Therapies

December 24th 2019

Precision Medicine Propels Research Efforts in Breast Cancer

December 5th 2019

Mark E. Robson, MD, provides a snapshot of the precision focus in breast cancer, as well as the emergence of biosimilars in the field.

Genomic Era Trials Drive Discovery

December 2nd 2019

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Vorasidenib, Ivosidenib Show Encouraging Activity in IDH1-Mutant Low-Grade Glioma

November 26th 2019

Single-agent vorasidenib or ivosidenib led to brain penetrance and 2-hydroxyglutarate suppression in patients with low-grade glioma who harbor IDH1 mutations.

Prognostic and Predictive Assays Guide Therapy Decisions in Breast Cancer

November 11th 2019

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

BRCA Rules Leave Patients Behind

November 1st 2019

Updated guidelines from the United States Preventive Services Task Force on BRCA1/2 genetic testing recommend risk assessment, counseling, and genetic test-ing for women who meet certain criteria but fall short of encompassing important groups of individuals who are at risk for developing BRCA1/2 mutation–driven disease

IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types

October 31st 2019

In the ongoing search for novel immunotherapies that might rival or surpass the efficacy of immune checkpoint inhibitors, drugs targeting IDO1—a key enzyme in tryptophan metabolism—have been a major focus in recent years.

Identification of Rare Biomarkers Leading to New Targeted Therapies in NSCLC

October 30th 2019

James P. Stevenson, MD, discusses available biomarker-driven therapies in non–small cell lung cancer, as well as rarer biomarkers under clinical investigation.